SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 328 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,636,624 | +68.6% | 417,725 | +59.3% | 0.10% | +56.1% |
| Q2 2023 | $30,038,596 | -44.3% | 262,300 | -32.9% | 0.07% | -51.1% |
| Q1 2023 | $53,888,360 | +1.7% | 390,977 | -4.4% | 0.14% | -6.9% |
| Q4 2022 | $53,011,178 | -35.9% | 409,100 | -45.3% | 0.14% | -42.9% |
| Q3 2022 | $82,741,000 | +185.5% | 748,515 | +93.6% | 0.25% | +167.4% |
| Q2 2022 | $28,980,000 | -2.3% | 386,601 | +1.8% | 0.10% | +1.1% |
| Q1 2022 | $29,665,000 | +119.7% | 379,731 | +153.3% | 0.09% | +100.0% |
| Q4 2021 | $13,501,000 | -61.9% | 149,928 | -60.9% | 0.05% | -68.2% |
| Q3 2021 | $35,441,000 | +180.7% | 383,236 | +136.0% | 0.15% | +146.7% |
| Q2 2021 | $12,624,000 | -34.6% | 162,389 | -37.3% | 0.06% | -36.8% |
| Q1 2021 | $19,296,000 | -49.7% | 258,907 | +15.0% | 0.10% | -55.4% |
| Q4 2020 | $38,378,000 | +6.0% | 225,109 | -11.5% | 0.21% | -7.8% |
| Q2 2019 | $36,207,000 | +23.0% | 254,256 | +3.0% | 0.23% | +17.9% |
| Q1 2019 | $29,429,000 | +101.8% | 246,905 | +84.8% | 0.20% | +86.7% |
| Q4 2018 | $14,584,000 | +80.0% | 133,639 | +166.3% | 0.10% | +183.8% |
| Q3 2018 | $8,104,000 | -79.0% | 50,176 | -82.8% | 0.04% | -78.9% |
| Q2 2018 | $38,514,000 | -14.1% | 291,376 | -51.8% | 0.18% | -6.4% |
| Q1 2018 | $44,834,000 | +564.9% | 605,122 | +399.3% | 0.19% | +790.5% |
| Q4 2017 | $6,743,000 | +43.2% | 121,196 | +16.8% | 0.02% | +16.7% |
| Q3 2017 | $4,708,000 | -6.8% | 103,789 | -30.8% | 0.02% | -14.3% |
| Q2 2017 | $5,054,000 | -61.1% | 149,933 | -65.9% | 0.02% | -65.6% |
| Q1 2017 | $13,002,000 | -2.0% | 439,245 | -9.2% | 0.06% | -14.1% |
| Q4 2016 | $13,266,000 | +86.5% | 483,643 | +317.4% | 0.07% | +73.2% |
| Q3 2016 | $7,115,000 | +4520.1% | 115,868 | +899.4% | 0.04% | +4000.0% |
| Q1 2015 | $154,000 | -97.1% | 11,594 | -91.7% | 0.00% | -98.9% |
| Q2 2013 | $5,325,000 | – | 140,000 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |